MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Kodu・Aktsiate loetelu・Altimmune Inc

Altimmune Inc

Suletud

4.76 -4.61

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

4.7

Max

5.12

Põhinäitajad
By Trading Economics
Sissetulek	-335K -23M
Müük	5K
Aktsiakasum	-0.33
Kasumimarginaal	-463,600
Töötajad	59
EBITDA	-344K -23M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+337.2% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	8. mai 2025

Turustatistika
By TradingEconomics
Turukapital	-16M 410M
Eelmine avamishind	9.37
Eelmine sulgemishind	4.76

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

N/A / 5.88 Toetus ja vastupanu

Altimmune Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

1. apr 2025, 23:15 UTC

Suurimad hinnamuutused turgudel

Hims & Hers Adds Eli Lilly's Zepbound in Expansion of Weight-Loss Offerings -- 2nd Update

1. apr 2025, 23:46 UTC

Market Talk

Market Grapples With Valuing Goodman's Data Centers -- Market Talk

1. apr 2025, 23:44 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1. apr 2025, 23:44 UTC

Market Talk

Global Equities Roundup: Market Talk

1. apr 2025, 23:44 UTC

Market Talk

Nikkei May Trade Rangebound Amid U.S. Tariff Uncertainty -- Market Talk

1. apr 2025, 23:43 UTC

Market Talk

Gold Steady, Underpinned by Signs of Chinese Buying Activity -- Market Talk

1. apr 2025, 23:11 UTC

Peamised uudised

Risk Off Trade Is Getting Crowded. It's More Worry Than Panic. -- Barrons.com

1. apr 2025, 23:02 UTC

Market Talk

New Zealand May Be Measuring Stick for Trade-War Fallout -- Market Talk

1. apr 2025, 22:31 UTC

Peamised uudised

Wilbur Ross Has Thoughts on Trump's Tariffs -- Barrons.com

1. apr 2025, 22:26 UTC

Market Talk

RBA's Focus on What It Doesn't Know Boosts May Cut Odds -- Market Talk

1. apr 2025, 21:47 UTC

Peamised uudised

Wilbur Ross Has Thoughts on Trump's Tariffs -- Barrons.com

1. apr 2025, 21:32 UTC

Peamised uudised

Hooters' Bankruptcy Is the Latest Sign of Trouble for Restaurants -- Barrons.com

1. apr 2025, 21:06 UTC

Market Talk

Mexican Remittances See Slow Start to the Year -- Market Talk

1. apr 2025, 21:00 UTC

Market Talk

ESG Roundup: Market Talk

1. apr 2025, 20:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Financial Services Roundup: Market Talk

1. apr 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

1. apr 2025, 20:47 UTC

Peamised uudised

Boeing Stock Drops. Why Lower 737 MAX Production Report Wasn't Quite Right. -- Barrons.com

1. apr 2025, 20:47 UTC

Peamised uudised

BYD Will Beat Tesla Two Ways This Quarter -- Barrons.com

1. apr 2025, 20:20 UTC

Peamised uudised

Trump's 'Liberation Day' Tariffs Loom; Treasury Yields Fall -- WSJ

1. apr 2025, 20:15 UTC

Omandamised, ülevõtmised, äriostud

Eaton Completes Acquisition Of Fibrebond >ETN

1. apr 2025, 20:11 UTC

Market Talk

Altria Stock Seen Overvalued Amid Steep Volume Losses -- Market Talk

1. apr 2025, 20:07 UTC

Omandamised, ülevõtmised, äriostud

Johnson & Johnson Intends to Complete Its Acquisition of Intra-Cellular Therapies on or Around April 2 >JNJ

1. apr 2025, 20:00 UTC

Peamised uudised

Americans Are Worried About Tariffs. Consumer Stocks Could Take a Hit. -- Barrons.com

1. apr 2025, 19:46 UTC

Peamised uudised

Visa, American Express Bidding to Win Apple Credit-Card Network, Sources Say -- WSJ

1. apr 2025, 19:43 UTC

Market Talk

Oil Rally Loses Momentum Ahead of U.S. Tariff Plans -- Market Talk

1. apr 2025, 19:17 UTC

Peamised uudised

Meta's Head of AI Research to Resign Amid Computing Push -- Update

1. apr 2025, 19:13 UTC

Market Talk

U.S. Natural Gas Futures Give Back Gains -- Market Talk

1. apr 2025, 19:03 UTC

Market Talk

Don't Rush Into Trade Talks With U.S., Canadian Experts Advise Lawmakers -- Market Talk

1. apr 2025, 19:00 UTC

Market Talk

Gold Slips Ahead of Tariff Day -- Market Talk

1. apr 2025, 18:54 UTC

Market Talk

Mexican Manufacturing PMIs Reflect Tariff Threats -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Altimmune Inc Prognoos

Hinnasiht

By TipRanks

337.2% tõus

12 kuu keskmine prognoos

Keskmine 21.86 USD 337.2%

Kõrge 28 USD

Madal 12 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Altimmune Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

8 ratings

Osta

Hoia

Müü

Põhineb 8 analüütiku instrumendi Altimmune Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

N/A / 5.88Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Altimmune Inc

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.